|
|
WuXi PharmaTech Reports Higher Q3
publication date: Nov 16, 2009
WuXi PharmaTech (药明康德), a bellwether for China’s CRO industry, reported a modest increase in Q3 revenues, but clearly feels the worst of the economic downturn is in the past. Revenues move up 10% to $70 million, and net income (non-GAAP) was 33% higher at $17.6 million. The company reiterated its guidance for 2009 revenues while raising its estimate for 2009 adjusted EBITDA. China-based Laboratory Services division is the company’s best performing segment. More details.. Stock Symbol: (NYSE: WX)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|